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The Gen-Probe PACE 2 assay (GP) in combination with a modified collection system was compared with cell
culture (CC) for the detection of Chlamydia trachonmatis in urethral specimens from males. Analysis of
discordant results was performed by PCR. The modifications, i.e., application of a more rigid swab type and
a 50%Y reduction in the amount of transport medium, were made to improve the sensitivity of the assay. By
using the modified GP on 302 urethral specimens from males, a sensitivity of 89.5% and a specificity of 100%o
were determined. In addition, performance of a probe competition assay on all GP samples with a result >0.6
and < 1.0 times the cutoff factor (gray zone) detected three more true-positive samples. The sensitivity of GP
in combination with the probe competition assay increased to 94.9%, with a specificity of 100%. This was
identical to the perfonnance of CC. The modified GP offers a very sensitive and specific alternative to CC.
Chlamydia trachomatis is now the most common cause of
sexually transmitted diseases (2). Among other serious com-
plications, it frequently leads to infertility in women (4). Cell
culture (CC) is considered the reference method for detec-
tion of C. trachomatis in clinical specimens. However, CC
requires at least 48 h of incubation and extensive laboratory
facilities. Furthermore, the reliability of CC may be influ-
enced substantially by transport and storage conditions (9).
Alternative methods aimed at overcoming these disadvan-
tages have been developed. Direct immunofluorescent-anti-
body tests and enzyme immunoassays were the first alterna-
tives. In several studies, variable sensitivities and
specificities were found (1, 5, 12). The reliabilities of these
methods are considered to be inferior to that of CC. More
recently, molecular biological methods have been devel-
oped. Both a DNA probe and a PCR assay are now com-
mercially available (3, 7, 13). In a former study (8), we
evaluated the GenProbe PACE 2 assay (GP), a nonisotopic
DNA probe assay, for the detection of C. trachomatis in
urogenital specimens. For samples from women, the perfor-
mance was comparable to that of CC (sensitivity, 95.2%;
specificity, 98.2%). However, for samples from men, the
sensitivity was lower (77.2%), but the specificity was high
(99.6%). The low level of sensitivity for samples from males
prompted the manufacturer to modify the swab and trans-
port system by reducing the volume of the transport medium
and using a more rigid swab. To evaluate whether these
modifications had improved the sensitivity of the assay, we
repeated the study with samples from males using the
modified GP. In addition, all GP-positive samples and all
samples showing discrepancies between CC and GP results
and all samples in a gray zone were tested by a probe
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competition assay (PCA) to improve the performance of the
assay.
Patients. Urethral samples were taken from 302 men
visiting the outpatient clinic for sexually transmitted dis-
eases at the University Hospital in Rotterdam, The Nether-
lands.
Sample collection. Samples for both GP and CC were
collected with dacron swabs and were placed into GP
transport medium or 0.2 M sucrose phosphate buffer, re-
spectively. The sampling order was, first, the sample for GP
and, thereafter, the sample for CC during the first half of the
study (149 samples). Then, the sampling order was reversed
(153 samples). The sample for GP was stored at 4°C. The
sample for CC was stored at 4°C or, when not tested within
24 h, at -70°C. All specimens were processed within 7 days.
The remainders of both samples were stored at -70°C for
further evaluation by PCA and PCR.
CC. CC was performed on cycloheximide-treated McCoy
cells in microtiter plates exactly as described previously (8).
Briefly, two wells per plate were each inoculated with 0.2 ml
of sample. After centrifugation, the supernatants were re-
placed with 0.1 ml of growth medium. The plates were
incubated at 37°C for 48 h, after which the monolayers were
fixed, stained with a fluorescent monoclonal antibody, and
examined for inclusions. CC results were scored as follows:
0, no inclusions per two wells; 1, 1 to 5 inclusions per well;
2, 6 to 20 inclusions per well; and 3, >20 inclusions per well.
GP. GP was performed according to the manufacturer's
instructions as described in our previous study (8). The
modifications in comparison with the previous version were
(i) the use of a more rigid swab and (ii) a 50% reduction in the
amount of transport medium that was used. The gray zone
was defined as >0.6 and <1.0 times the cutoff factor.
PCA. PCA is a rapid DNA probe test which can be used in
combination with GP. It uses competitive nucleic acid hy-
bridization to differentiate a true-positive signal from a
false-positive signal. All samples which tested positive in the
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TABLE 1. GP results in comparison with CC results for
detection of C. trachomatisa
No. of samples with the following CC result:
GP result
Positive Negative Total
Positive 33 1 34
Negative 6 262 268
Total 39 263 302
a Sensitivity of GP, 33 of 39 samples (84.6%); specificity of GP, 262 of 263
samples (99.6%); predictive value of a positive GP result, 33 of 34 samples
(97.1%); predictive value of a negative GP result, 262 of 268 samples (97.8%).
GP, all samples showing discrepancies between CC and GP,
and all samples in the gray zone were retested by both GP
and PCA in the same run. For PCA, 100 ,ul of patient sample
was added to the PCA tube. This tube contained lyophilized
probe reagent that was identical to the GP probe reagent
except that it lacked the chemiluminescent label. Then, 100
,u of standard chemiluminescent-labeled probe was added to
the PCA tube. Because the labeled and unlabeled probes are
complementary to the rRNA of the target organism, they
compete with one another to form a stable RNA-DNA
hybrid with the target. Replacement of the labeled probe by
the unlabeled probe results in a reduction of the signal. If this
reduction is 70% or greater in comparison with the GP result
from the same run, the sample is considered true positive. A
lower level of reduction of the signal indicates that the
positive GP result was caused by nonspecific hybridization
and should be considered negative.
PCR. PCR was used for the analysis of discordant GP and
CC results. The remainders of both the samples for GP and
CC, which were stored at -70°C, were therefore examined
without knowledge of the initial test results. The PCR
technique used in the present study was identical to that
used in the former study (8).
Statistics. Statistical evaluation of the collected data was
performed by using Fisher's exact test. Statistical signifi-
cance was accepted at P < 0.05 (two-tailed).
Urethral samples from 302 men were evaluated by CC and
GP. Thirty-nine samples were positive by CC, giving a
prevalence of 13%. The results of GP in comparison with
those of CC are given in Table 1. With CC as the reference
method, the sensitivity of GP was 84.6% and the specificity
was 99.6%. The results of PCA for all samples positively GP
were positive. Ten samples tested by GP and CC were either
discordant or had a GP result in the gray zone. Of these 10
samples, the sample tested by GP was retested by PCA and
the samples for both GP and CC were retested by PCR. The
results of this analysis are given in Table 2. Results for
patients 1 through 3 showed a discordance, which was
confirmed by PCR. Because the outcomes of both CC and
GP were confirmed by PCR for these samples, the discor-
dances were considered to be a result of swab-to-swab
variability and were omitted from further analysis. This left
299 evaluable patients. The following interpretations were
made. If the CC result was not confirmed by PCR on the
sample for CC, this was considered a false-positive CC
result. Accordingly, if the GP result was not confirmed by
PCR of the sample for GP, this was considered a false-
positive GP result. The performances of both GP and CC
were recalculated. Table 3 shows the sensitivities, specific-
ities, and positive and negative predictive values of CC and
GP and of CC and GP in combination with PCA for the
samples in the gray zone.
For evaluation of the performances of noncultural meth-
ods of detecting C. trachomatis, CC has long been consid-
ered the "gold standard." However, several studies have
clearly demonstrated that the sensitivity of CC is insufficient
for this purpose (8, 11, 13). Most of the recent studies
therefore use either a combination of tests (3, 13) or confir-
matory tests on the initial sample (8, 11) as a reference
method. In the current study, we used a confirmatory PCR
on the initial samples to analyze discordant results. By this
method, the one false-positive GP result in the comparison
with CC was shown to be caused by a failure of CC (Table 2,
sample 10). This increased the specificity of GP and de-
creased the sensitivity of CC. Two of the six false-negative
GP results were caused by swab-to-swab variability (Table
2, samples 1 and 2). The other four false-negative GP results
were indeed false negative (Table 2, samples 5 to 8). The
recalculated sensitivity of GP was 89.5% (34 of 38 samples),
in comparison with 97.4% (37 of 38 samples) for CC. The
specificities of both GP and CC were 100% (Table 3). In
comparison with the results from the former study (8),
before the modifications, the sensitivity of GP increased
from 77.2 to 89.5%. This difference was not statistically
significant.
TABLE 2. Patient samples showing discrepancy between CC and GP results and with a GP result in the gray zone and results of PCA
and interpretation after analysis by PCR
GP result CC result
Sample no. PCA category Interpretation
RLUa Category PCR Score" Category PCR
1 218 - - 1 + + - Swab-to-swab variability
2 286 _ _ 1 + + - Swab-to-swab variability
3 379 -+ + 0 - - + Swab-to-swab variability
4 286 + - 0 - - - True-negative GP result
5 191 - + 1 + + - False-negative GP result
6 186 - + 2 + + + False-negative GP result
7 256 + + 1 + + + False-negative GP result'
8 367 + + 1 + + + False-negative GP resultd
9 346 + + 0 - + + False-negative CC result
10 23,834 + + 0 - + + False-negative CC result
a RLU, GP result, in relative light units.
b Score, score of CC for interpretation; see text.
c +, GP result in the gray zone (>0.6 and <1.0 times the cutoff factor).
dFalse-negative GP result but positive by PCA on the GP samples in the gray zone.
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TABLE 3. Sensitivities, specificities, and predictive values of
CC and GP and of CC and GP in combination with
PCA on samples in the gray zone
Percent
Test Predictive value
Sensitivity Specificity
Positive Negative
CC versus GP
CC 97.4 100 100 99.6
GP 89.5 100 100 98.5
CC versus GP and PCA
CC 94.9 100 100 99.2
GP 94.9 100 100 99.2
Since no false-positive GP results obtained by GP were
found in the present study, we could not evaluate the value
of PCA for improving the specificity of GP. However,
application of PCA on the samples for GP in an arbitrarily
chosen gray zone (>0.6 and <1.0 times the cutoff factor)
improved the sensitivity of the assay. Six samples in the gray
zone were identified. One sample (Table 2, sample 2) was
negative by PCA but positive by CC. Another sample (Table
2, sample 3) was positive by PCA but negative by CC.
Analysis by PCR showed that both of these discrepancies
were caused by swab-to-swab variability. One sample (Table
2, sample 4) was negative by PCA. PCR of the samples for
GP and CC was negative. This was a true-negative GP result.
Two samples in the gray zone (Table 2, samples 7 and 8)
were positive by PCA and CC. These were initially negative
by GP. So, PCA was able to detect two more true-positive
samples, and thus increased the sensitivity of the GP. The
last sample in the gray zone (Table 2, sample 9) was negative
by CC. PCR analysis was positive for the samples that tested
positive by GP and negative by CC. This was an additional
false-negative CC result and the third additional true-posi-
tive PCA result. Table 3 shows the sensitivity, specificity,
and positive and negative predictive values of both CC and
GP after application ofPCA on the samples in the gray zone.
Both CC and GP detected 37 of 39 true-positive samples
(sensitivity, 94.9%). The specificities of both assays were
100%. The sensitivity of GP with PCA of samples in the gray
zone was statistically significantly greater than the sensitiv-
ity obtained in the former study (8).
Blocking assays were evaluated in combination with en-
zyme immunoassays. Blocking assays are primarily used to
increase the specificities of these assays (6, 10), but the
sensitivities can also be improved by applying blocking
assays to samples that test in the gray zone (6). In this
evaluation, the specificity of GP was already optimal without
the application of PCA. In our previous study (8), the
specificity of GP for cervical samples was 98.2%. PCA could
improve the specificity for samples from females; this appli-
cation should be evaluated. Although the number of samples
in the gray zone was small, the application of PCA on these
samples improved the sensitivity from 89.5 to 94.9%. The
application of PCA in combination with GP looks promising
and deserves further evaluation to optimize the diagnosis of
C. trachomatis in urogenital specimens. PCA is not yet
available for diagnostic purposes.
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